SCHEMBL26460261

SCHEMBL26460261

COc1ccc(-c2ccc3cnc(C(F)(P)P)n3c2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 6/20 0.60
RAB9A P51151 3/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HSD17B10 Q99714 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALDH1A3 P47895 1/20 0.37
FLT3 P36888 2/20 0.36
SCN1A P35498 1/20 0.36
SCN2A Q99250 1/20 0.36
PLK4 O00444 1/20 0.36
AURKA O14965 1/20 0.36
DYRK3 O43781 1/20 0.36
MAP4K4 O95819 1/20 0.36
NTRK1 P04629 1/20 0.36
INSR P06213 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL932813 0.89 SCN5A (0.75) SCN5ARAB9AKDM4EMEN1ALDH1A1
SCHEMBL26460412 0.88 SCN5A (0.61) SCN5ARAB9AKDM4EMEN1ALDH1A1
SCHEMBL26462399 0.84 SCN5A (0.64) SCN5ASCN1ASCN2A
SCHEMBL26460368 0.84 SCN5A (0.61) SCN5ASCN1ASCN2A
SCHEMBL26460521 0.84 SCN5A (0.57) SCN5ARAB9AKDM4EMEN1ALDH1A1
SCHEMBL26460440 0.79 SCN5A (0.64) SCN5ARAB9AKDM4EMEN1ALDH1A1
SCHEMBL26462424 0.78 SCN5A (0.56) SCN5ARAB9AKDM4EMEN1ALDH1A1
SCHEMBL26460459 0.78 SCN5A (0.56) SCN5ARAB9AKDM4EMEN1ALDH1A1
SCHEMBL26460337 0.78 SCN5A (0.63) SCN5ASCN1ASCN2ASCN10A
SCHEMBL26459346 0.77 RAB9A (0.57) SCN5ARAB9AKDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230134428-A1 FUSED HETEROARYL COMPOUNDS, AND METHODS THEREOF FOR TREATING DISEASES, DISORDERS, AND CONDITIONS RELATING TO ABERRANT FUNCTION OF A SODIUM CHANNEL PRAXIS PRECISION MEDICINES, INC. 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230134428-A1 FUSED HETEROARYL COMPOUNDS, AND METHODS THEREOF FOR TREATING DISEASES, DISORDERS, AND CONDITIONS RELATING TO ABERRANT FUNCTION OF A SODIUM CHANNEL SCN1A, SCN3A, SCN2A SCN5A 7/4885RAB9A 636/4885KDM4E 3287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.